Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

LEU AML - DA 3+10 [DAUNOrubicin and cytarabine] induction [course 1]

Treatment Overview

DA 3+10 course 1 is followed (after 28 days or on count recovery) by a second induction course of treatment which is selected based on response to treatment and risk stratification.

Cycle 1 - 28 days - Course 1

Cycle length:
28

Cycle details

Cycle 1 - 28 days - Course 1

Medication Dose Route Days Max Duration
DAUNOrubicin * 60 mg/m² Once daily intravenous 1, 3, 5 Min: 60 minutes
cytarabine 100 mg/m² Twice daily intravenous 1 to 10 15 minutes

Full details

Cycle 1 - 28 days - Course 1

Day: 1

Medication Dose Route Max duration Details
DAUNOrubicin * 60 mg/m² Once daily intravenous Min: 60 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.

cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 2

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 3

Medication Dose Route Max duration Details
DAUNOrubicin * 60 mg/m² Once daily intravenous Min: 60 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.

cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 4

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 5

Medication Dose Route Max duration Details
DAUNOrubicin * 60 mg/m² Once daily intravenous Min: 60 minutes
Instructions:

Warning vesicant—ensure vein is patent prior to administration, administer vesicant as per institutional policy and monitor for signs of extravasation throughout administration.

cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 6

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 7

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 8

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 9

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Day: 10

Medication Dose Route Max duration Details
cytarabine 100 mg/m² Twice daily intravenous 15 minutes
Instructions:

Every 12 hours.

Supportive Care Factors

Factor Value
Antifungal prophylaxis: Routine antifungal prophylaxis recommended
Antiviral prophylaxis for herpes virus: Routine antiviral prophylaxis recommended
Emetogenicity: Variable
Tumour lysis syndrome prophylaxis: Tumour lysis syndrome prophylaxis is recommended

Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.

Emetogenicity: MEDIUM days 1, 3, 5; LOW days 2, 4, 6, 7, 8, 9, 10.

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.